Abstract:In December 2002, the Safety Working Party (SWP) of the European Committee for Proprietary Medicinal Products (CPMP) published a “Position paper on the limits of genotoxic impurities”. The European Union intended to supplement a gap in the International Conference on Harmonisation (ICH) guidelines on qualification of impurities, as it was deemed that impurities with genotoxic potential were a special case not specifically covered in terms of qualification by the Q3A and Q3B guidelines. In fact, the SWP’s proposed approach follows a safety factor-based risk assessment process similar to that in ICH Guideline Q3C on limits for residual solvents, rather than a qualification process as described in ICH Q3A and B.The need to provide particular advice for the control of drug substance impurities that bear the risk of non-reversible toxicity (e.g. genotoxic impurities) is widely acknowledged. If such impurities can be shown to exert their genotoxicity via a mechanism with a threshold, then control of the impurity according to calculated permitted daily exposures (PDEs) should not pose major problems. However, in most cases, threshold mechanisms for such genotoxic impurities will not have been demonstrated. Employing conservative uncertainty factors to calculate PDEs in such cases may lead to limits that could be out of proportion to the impurity qualification limits (as per ICH quality guidelines), normally 1500 parts per million (≡ 1.5mg/1g substance), and orders of magnitude lower than exposures to genotoxins via other sources, such as diet and the environment. Alternative approaches based on the calculation of a lifetime cancer risk of 1/105 or 1/106, which have been recommended for control of carcinogens in other circumstances, should be considered. This could lead to more realistic limits for genotoxic impurities, e.g. an intake of up to 1.5 μg/day for most genotoxic impurities without evidence of a threshold is considered to be toxicologically insignificant. Control of ‘suspect’ or ‘known’ potentially genotoxic impurities at such a level is important when one considers that many genotoxins present in drug substance at much higher concentrations would escape detection during standard genotoxicity testing of drug substance. Whilst a generic limit of 1.5 μg/day of an identified genotoxin may be suitable for chronic use drugs in a wide patient population, higher levels may be acceptable for shorter duration use, and in circumstances involving closely-defined patient populations, for example, where a case-specific assessment is appropriate.

Strategies for the identification, control and determination of genotoxic impurities in drug substances: A pharmaceutical industry perspective

Identification, control strategies, and analytical approaches for the determination of potential genotoxic impurities in pharmaceuticals: A comprehensive review

Control of Genotoxic Impurities in Active Pharmaceutical Ingredients: A Review and Perspective

Regulation of genotoxic and carcinogenic impurities in drug substances and products

A Brief Review on Genotoxic impurities in Pharmaceuticals

Evaluation and Control of Genotoxic Impurities in Active Pharmaceutical Ingredients

GENOTOXIC IMPURITIES: AN IMPORTANT REGULATORY ASPECT

The Assessment of Impurities for Genotoxic Potential and Subsequent Control in Drug Substance and Drug Product

A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity

Overview of Genotoxic Impurities in Pharmaceutical Development

Modern Approaches to Estimating the Content of Genotoxic Impurities in Drugs (a Review)

Risk Assessment of Genotoxic Impurities in New Chemical Entities: Strategies To Demonstrate Control

A Review on Carcinogenic Impurities Found in Marketed Drugs and Strategies for its Determination by Analytical Methods

Safety assessment of drug impurities for patient safety: A comprehensive review

Recent advances in trace analysis of pharmaceutical genotoxic impurities

A Comprehensive Review on Assessment and Key Control Strategies for Impurities in Drug Development with a Special Emphasis on Post-marketing Surveillance

NDSRIs Crisis in Pharmaceuticals; Insights on Formation Pathways, Root Causes, Risk Management, and Novel Analytical Techniques

Setting Limits for Genotoxic Impurities in Drug Substances

Risk Assessment of Genotoxic Impurities in Marketed Compounds Administered over a Short-Term Duration: Applications to Oncology Products and Implications for Impurity Control Limits

NDSRIs Crisis in Pharmaceuticals; Insights on Formation Pathways, Root Causes, Risk Management, and Novel Analytical Techniques.